Skip to content

    Granules India

    GRANULESGood
    Healthcare·28 May 2025
    Management Summary

    Granules India reported a mixed Q4 FY25, with modest revenue growth and strong margin expansion driven by a shift towards high-margin formulation products. The company is actively addressing a US FDA warning letter at its Gagillapur facility, which is expected to cause operational slowdowns for the next two quarters. Strategic initiatives include the acquisition of Senn Chemicals for peptide therapeutics, commissioning of Phase-1 and Phase-2 of the Genome Valley formulation facility, and expansion of its oncology and ADHD portfolios, positioning the company for future growth despite near-term regulatory challenges.

    Highlights

    8
    • Q4 FY25 Revenue stood at ₹11,974 million, marking a 2% YoY growth and 5% QoQ growth.

    • Full Year FY25 Revenue was ₹44,816 million, a slight decline from ₹45,064 million in FY24.

    • Q4 FY25 Gross Margin improved to 63.4%, up 333 basis points YoY and 169 basis points QoQ, driven by higher finished dosages.

    • Q4 FY25 EBITDA was ₹2,524 million, with an EBITDA margin of 21.1%, a decrease of 67 basis points YoY but an increase of 83 basis points QoQ.

    • FY25 EBITDA grew 10% YoY to ₹9,452 million.

    • R&D spend for FY25 increased 20% to ₹2,377 million (vs ₹1,990 million in FY24).

    • Net Debt reduced to ₹7,061 million in Q4 FY25 from ₹8,289 million in Q3 FY25.

    • Gagillapur facility received an FDA warning letter on February 26, 2025, with remediation efforts expected to impact operations for another 1-2 quarters.

    Concerns

    2
    • US FDA Warning Letter for Gagillapur facility

    • Slowdown of operations due to remediation efforts

    What Changed2

    vs Q1 FY26

    Guidance items17 → 11 (-6)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue11,974 Mn+1.8%YoY
    2. 02EBITDA2,524 Mn-1.3%YoY
    3. 03EBITDA Margin21.1%-0.7%YoY
    4. 04Gross Margin63.4%+3.3%YoY
    5. 05R&D Spend665 Mn+9.2%YoY

    Guidance & targets

    11
    CategoryTargetPriority
    Operations
    Gagillapur Production Disruption
    1-2 quarters
    High
    Revenue
    FY26 Revenue
    better than last year
    Medium
    Revenue
    Oncology Portfolio Revenue
    start yielding revenues
    Medium
    Expenses
    Gagillapur Remediation Expenses
    continue
    High
    Sales
    Senn Chemicals Annual Sales
    CHF20 million
    High
    Profitability
    Senn Chemicals Profitability
    around breakeven/slight loss
    Medium
    Capex
    Overall CAPEX
    ₹600 crores
    High
    Capacity
    GLS Phase-II Dosage Capacity
    7.5 billion
    High
    Capacity Utilization
    GLS Phase-II Capacity Utilization
    40-50%
    Medium
    Capacity Utilization
    GLS Phase-II Capacity Utilization
    close to 90%
    Medium
    Product Mix
    API/PFI Contribution to Revenue
    less than 25%
    High

    Risks & concerns

    5
    RiskSeverity

    US FDA Warning Letter for Gagillapur facility

    Received on Feb 26, 2025, following August 2024 inspection with six Form 483 observations; classified as official action initiated. Does not affect supply of approved commercial products but may temporarily impact FDA review of pending submissions.Management acknowledged

    high

    Slowdown of operations due to remediation efforts

    Ongoing remediation measures have resulted in a slowdown of operations, impacting Q4 output and expected to continue for another 1-2 quarters (Q1 and Q2 FY26).Management acknowledged

    high

    API price erosion and demand issues

    Continuous price erosion and demand issues in API and PFI segments impacted sales growth. Management is shifting focus to converting API into PFIs and FDs to mitigate this.Management acknowledged

    medium

    Potential US tariffs

    Management acknowledges potential impact of impending tariffs on US business, stating prices would have to increase, but believes it would be a level playing field.Analyst acknowledged

    medium

    Areas of Evasion(1)

    • Specific FY26 revenue/EBITDA guidance

    Q&A highlights

    3

    “Tushar, we are analyzing the whole situation. There is going to be a lot of CAPEX that has to come up in Switzerland. And also, we are putting up a peptide R&D facility in Hyderabad, and which will be followed by a peptide manufacturing also... It's sort of breakeven or slight loss as of today, yes. And we think in the next one or two quarters or three quarters it will continue to be around that level, but going forward with the new strategy, it should improve.”

    Reveals the significant future CAPEX commitment for Senn Chemicals and peptide expansion, along with its current breakeven/loss status, impacting near-term financials.

    asked by Tushar Manudhane

    3 min read6 chapters

    Detailed Narrative

    01

    Gagillapur Facility FDA Remediation Update

    Granules India's Gagillapur finished dosage facility received a US FDA warning letter on February 26, 2025, following an August 2024 inspection with six Form 483 observations. While commercial product supply remains unaffected, the warning letter may temporarily impact FDA review of pending product submissions. Remediation efforts, guided by three consulting firms, have led to a slowdown in operations, which impacted Q4 output and is expected to continue for another one to two quarters. The company has tested over 1,200 batches and 2,600 swab/rinse samples, all within acceptable limits, and expects remediation expenses of approximately ₹60 crores for FY25, continuing into Q1 and Q2 FY26.

    02

    Strategic Acquisition of Senn Chemicals and Peptide Foray

    Granules has strategically acquired Senn Chemicals, a Swiss-based CDMO, marking its entry into the high-growth peptide therapeutic space, including GLP-1 receptor anti-agonists. Senn Chemicals currently generates roughly CHF20 million in annual sales and operates at a breakeven or slight loss, which is expected to continue for the next 1-3 quarters. Granules plans significant CAPEX in Switzerland and for a new peptide R&D and manufacturing facility in Hyderabad, aiming to leverage Senn's capabilities for both CDMO business and Granules' own GLP-1 API and formulation development.

    03

    Genome Valley Formulation Facility Progress

    The new formulation facility at Genome Valley under Granules Life Sciences is progressing well. Phase-1, with a capacity of 2.5 billion dosages, has been commissioned, and commercial dispatches of monograph products are ongoing. Phase-2, adding an additional 7.5 billion dose capacity, has been commissioned in Q4 FY25 and is expected to be fully operational by next month. The company anticipates 40-50% capacity utilization by the end of FY26 and close to 90% by the end of FY27, pending FDA and European agency inspections expected in Q2 FY26.

    04

    R&D Investment and Portfolio Expansion

    Granules' R&D spend increased by 20% to ₹2,377 million in FY25, demonstrating a strong commitment to portfolio expansion. The company filed three US ANDAs and six European dossiers in Q4 FY25, bringing the total to 127 dossiers across regions. Significant progress has been made in the ADHD portfolio, with 10 products in the pipeline, including the launch of lisdexamfetamine capsules and chewable tablets in Q4 FY25. The oncology pipeline also includes around 10 products under development, with the first US ANDA and European filing submitted in Q4 FY25, expected to yield revenues from FY28 onwards.

    05

    Financial Performance and Margin Improvement

    Q4 FY25 revenue grew 2% YoY to ₹11,974 million, while full-year FY25 revenue was ₹44,816 million. Gross margin significantly improved to 63.4% in Q4 FY25, up 333 basis points YoY, primarily due to a strategic shift towards higher-margin formulation products. EBITDA for Q4 FY25 was ₹2,524 million (21.1% margin), a slight YoY decline but an 83 basis point QoQ improvement. Full-year EBITDA grew 10% to ₹9,452 million, despite increased professional expenses for FDA remediation and higher R&D costs. Net debt reduced to ₹7,061 million in Q4 FY25 from ₹8,289 million in Q3 FY25.

    06

    API/PFI Strategy and Geographical Mix

    Granules is strategically reducing its reliance on API sales, with the API/PFI segment contributing less than 25% of current revenue and expected to remain in that range going forward. The focus is on vertical integration, converting most APIs into PFIs and FDs for in-house consumption, especially for paracetamol where global overcapacity exists. North America remains the biggest growth driver, accounting for 79% of Q4 FY25 revenues. The company is also expanding filings in Europe (11 filings in FY25) and other ROW markets to diversify its geographical revenue mix, although the US market will continue to be a primary focus due to its size.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.